SILO Silo Pharma, Inc.
Financings ·
Silo Pharma agreed on October 13, 2026 to buy certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock. The shares are locked up for up to twelve months, and the 8-K names no underwriter or placement agent.
Silo Pharma agreed on October 1, 2026, to acquire software, technology and intellectual property from Norsight Consulting in exchange for a warrant to buy 300,000 shares.
Silo agreed on August 18, 2026 to buy software, technology and domain names from Parkview Consulting LLC, paying with shares subject to a lock-up of up to twelve months.
Silo agreed to sell 619,965 shares and warrants at $6.452 per share, with H.C. Wainwright & Co. as exclusive placement agent. The company expects about $4 million upfront.
Nasdaq told Silo it regained compliance with the minimum closing bid price requirement as of June 17, 2026, and the matter is now closed.
The Nevada certificate took effect on June 2, 2026, and shares began trading split-adjusted on Nasdaq on June 3. The ticker stays SILO under a new CUSIP number.
Silo filed an 8-K covering an asset purchase from Many Ads Inc. paid for with 2,100,000 shares of common stock. The filing names no underwriter or placement agent.
Silo Pharma did not regain the $1.00 minimum bid price by December 24, 2025, and Nasdaq granted it a second 180-day period to June 22, 2026. The company has told Nasdaq it may use a reverse stock split to cure the deficiency, and its annual report shows an accumulated deficit of $15,264,691.
Nasdaq notified Silo Pharma on June 27, 2025 that its common stock has not met the $1.00 minimum bid price. The company has until December 24, 2025 to regain compliance, and may consider a reverse stock split if needed.
Nasdaq told Silo Pharma on June 27, 2025 that its common stock fell below the $1.00 minimum bid price, based on closing bids from May 14 to June 26. The company has until December 24, 2025 to regain compliance and says it may consider a reverse stock split.
Silo Pharma, Inc. describes itself as a developmental stage biopharmaceutical and cryptocurrency company. Its therapeutics focus is on underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia and central nervous system diseases, using conventional drugs and psychedelic formulations. Its lead program, SPC-15, is an intranasal serotonin 4 (5-HT4) receptor agonist for PTSD and stress-induced anxiety disorders. The company holds an exclusive license agreement with Columbia University entered into July 1, 2024, and a license with Medspray Pharma BV for its soft mist nasal spray technology. It held a pre-IND meeting with the FDA in September 2024 and says it is aiming for an IND submission in 2026. SP-26 is a ketamine-based injectable dissolvable polymer implant for fibromyalgia and chronic pain and is in preclinical research. SPC-14 targets Alzheimer's disease, and SPU-16 is a CNS-homing peptide with initial research in multiple sclerosis; both are preclinical. The text also says the company plans to pursue rights to treat rare diseases.
| Product or program | What it is | Stage |
|---|---|---|
| SPC-15 | Intranasal 5-HT4 receptor agonist for PTSD and stress-induced anxiety disorders | preclinical, IND-enabling studies |
| SP-26 | Ketamine-based implant for fibromyalgia and chronic pain | preclinical research |
| SPC-14 | Compound targeting glutamate and serotonin receptors for Alzheimer's disease | preclinical |
| SPU-16 | CNS-homing peptide with initial research in multiple sclerosis | preclinical |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $72,102 | $72,102 |
| Research and development | $2.2 million | $2.4 million |
| Net income (loss) | -$4.2 million | -$4.4 million |
| Cash from operations | -$4.7 million | -$3.8 million |
| Cash and equivalents | $4.7 million | $3.9 million |
| Short-term investments | $2.1 million | $3.2 million |
Our latest story on this, dated Jun 1, 2026: "Silo Pharma completes 1-for-15 reverse stock split". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 10, 2026: "Silo prices up to $11.7 million private placement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 29, 2025: "Silo Pharma gets second 180 days from Nasdaq to meet $1.00 minimum bid price". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 2, 2026: "Silo Pharma buys Norsight software assets for a warrant". The story links the filing or release it is based on. Read the story.
Silo Pharma, Inc. trades under the ticker SILO on NASDAQ.
Silo Pharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Silo Pharma, Inc. is 1514183. Its filings are on SEC EDGAR.
1,588,250 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Silo Pharma, Inc. under United States.
Our directory classifies Silo Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Silo Pharma, Inc. is US82711P3001.
aibio.space lists Silo Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Silo Pharma, Inc. describes itself as a developmental stage biopharmaceutical and cryptocurrency company. Its therapeutics focus is on underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia and central nervous system diseases, using conventional drugs and psychedelic formulations.
SPC-15: Intranasal 5-HT4 receptor agonist for PTSD and stress-induced anxiety disorders Stage: preclinical, IND-enabling studies.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio